Kazia Therapeutics (KZIA) has released an update.
Kazia Therapeutics has announced promising results from the GBM AGILE phase II/III trial for their drug paxalisib, showing a significant improvement in overall survival for newly diagnosed unmethylated glioblastoma patients. The company plans to discuss accelerated approval pathways with the FDA, following favorable outcomes which include an approximate 33% increase in survival compared to current standard treatments. Paxalisib has been well-tolerated with consistent secondary analysis results, and full data is expected to be presented later in the year.
For further insights into KZIA stock, check out TipRanks’ Stock Analysis page.